Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
TFI-H8226 | Human | Biotinylated Human TFPI Protein, His Tag, ultra sensitivity (primary amine labeling) | ![]() |
![]() ![]() |
|
TFI-H5226 | Human | Human TFPI Protein, His Tag (active enzyme) | ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Befovacimab | BAY-109; BAY-1093884 | Morphosys Ag, Bayer AG | Details | ||
ARC-19499 | BAX-499; ARC-19499 | Archemix | Details | ||
KN-057 | KN-057 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Hemophilia A; Hemophilia B | Details |
Concizumab | NN-7415; mAb-2021; Anti-TFPI; mAbTFPI2021; NNC-172-2021; NNC-0172-2021; NNC-0172-0000-2021 | Phase 3 Clinical | Novo Nordisk A/S | Hemophilia A; Hemophilia B; Hemorrhage | Details |
Marstacimab | PF-6741086; PF-06741086 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Hemophilia A; Hemophilia B; Hemorrhage | Details |
This web search service is supported by Google Inc.